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Abstract
Background and Aims
The advent of highly effective hepatitis C (HCV) treatments has questioned the need for a
vaccine to control HCV amongst people who inject drugs (PWID). However, high treatment
costs and ongoing reinfection risk suggest it could still play a role. We compared the impact
of HCV vaccination amongst PWID against providing HCV treatment.
Methods
Dynamic HCV vaccination and treatment models among PWID were used to determine the
vaccination and treatment rates required to reduce chronic HCV prevalence or incidence in
the UK over 20 or 40 years. Projections considered a low (50% protection for 5 years), mod-
erate (70% protection for 10 years) or high (90% protection for 20 years) efficacy vaccine.
Sensitivities to various parameters were examined.
Results
To halve chronic HCV prevalence over 40 years, the low, moderate and high efficacy vac-
cines required annual vaccination rates (coverage after 20 years) of 162 (72%), 77 (56%)
and 44 (38%) per 1000 PWID, respectively. These vaccination rates were 16, 7.6 and 4.4
times greater than corresponding treatment rates. To halve prevalence over 20 years nearly
doubled these vaccination rates (moderate and high efficacy vaccines only) and the vacci-
nation-to-treatment ratio increased by 20%. For all scenarios considered, required annual
vaccination rates and vaccination-to-treatment ratios were at least a third lower to reduce
incidence than prevalence. Baseline HCV prevalence had little effect on the vaccine’s
impact on prevalence or incidence, but substantially affected the vaccination-to-treatment
ratios. Behavioural risk heterogeneity only had an effect if we assumed no transitions
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between high and low risk states and vaccinations were targeted or if PWID were high risk
for their first year.
Conclusions
Achievable coverage levels of a low efficacy prophylactic HCV vaccine could greatly reduce
HCV transmission amongst PWID. Current high treatment costs ensure vaccination could
still be an important intervention option.
Introduction
Hepatitis C virus (HCV) is a blood-borne disease with an estimated 80 million viraemic infec-
tions worldwide[1]. HCV infection can result in liver cirrhosis[2], with associated risks of liver
failure and hepatocellular carcinoma.
In developed countries, the primary mode of transmission is through injecting drug use[3].
Globally, HCV sero-prevalence amongst people who inject drugs (PWID) is 60%[4]. Preven-
tion of HCV among PWID is critical to reducing HCV transmission and HCV-related
morbidity.
Needle and syringe programmes (NSPs) and opiate substitution therapy (OST) can reduce
the risk of acquiring HCV[5] but may be insufficient for reducing HCV prevalence to low lev-
els[6]. Modeling has shown the potential benefits of HCV treatment as prevention, particularly
with new highly effective direct-acting antiviral therapies (DAAs)[7, 8]. However, the high
costs of these treatments (>$85,000 and $54,000 for a 12-week course of Sofosbuvir in the
USA and UK respectively[9] and $94,500 for a 12-week course of Harvoni[10]) currently
restricts their widespread use for prevention.
An alternative prevention strategy could be vaccination. Early HCV vaccine studies in chim-
panzees found that a vaccine eliciting a high efficacy humoral response effectively controlled
and facilitated clearance of the homologous HCV genotype 1a challenge virus[11]. Phase I
studies conducted in humans demonstrated that the vaccine was safe and well tolerated and
that some individuals elicited broadly reactive neutralizing antibodies (NAbs)[12], although
development of this vaccine has since stalled because HCV has numerous immune evasion
strategies that limit the effectiveness of the NAb response[13]. An alternative approach that
generates T-cell responses has also been tested in human phase 1 studies and was well tolerated
and highly immunogenic[14]. Ongoing phase 2 trials amongst PWID are determining the effi-
cacy of this vaccine[15]. Thus, a partially effective prophylactic HCV vaccine could soon
become available. It is, therefore, important to assess the possible utility of HCV vaccination
for HCV prevention and to compare its impact against new highly effective DAAs.
Methods
We developed a dynamic deterministic HCV transmission model among PWID incorporating
prophylactic vaccination to determine the annual vaccination rates required to reduce chronic
prevalence and incidence amongst PWID by 25, 50 and 75% over 20 and 40 years. Using a
HCV treatment model[7], we determined the corresponding annual treatment rates that
achieve the same impact and calculate the corresponding ratio of the vaccination to treatment
rates.
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Mathematical model: vaccine
The vaccine model includes three groups of PWID (Fig 1A): susceptible (including spontane-
ously cleared infections), chronically infected, and vaccinated (model equations in S1 File).
Acute infection was not included because previous modelling suggests it contributes little to
transmission[6, 7].
New PWID enter the susceptible pool at fixed rate θ and leave all compartments either
through death or permanent cessation of injection (rate μ). The model is dynamic, with the
rate of infection of susceptible PWID being proportional to the prevalence of chronic infection
and infection rate, λ. Acute infection spontaneously clears in a proportion, α, who remain sus-
ceptible. The remaining infected fraction, (1—α) progress to chronic infection.
A fixed number (Fv) of susceptible (RNA-negative) PWID are vaccinated annually unless
the number of susceptible PWID is below Fv, whereupon all susceptible PWID are vaccinated.
PWID remain in the vaccinated state for an average duration 1\δ where they experience a fac-
tor η lower infection rate than susceptible PWID, giving 100(1-η)% as the degree to which the
vaccine reduces the risk of HCV acquisition or the vaccine efficacy. PWID losing protection
from the vaccine re-enter the susceptible pool, and can be revaccinated without a loss in
protection.
Mathematical model: treatment
Fig 1B shows the model schema[7] used to project the prevention impact of IFN-free DAAs
(model equations in S1 File). The model dynamics for entry, exit and infection are identical to
the vaccine model, with the only model difference being the intervention component. In this
model, a fixed number (Ft) of chronically infected PWID are treated each year. If the treatment
rate exceeds the number of chronically infected PWID, then all are treated. PWID undergoing
treatment are assumed to be non-infectious due to rapid reductions in viral load when on treat-
ment[16] and, given the different treatment options available, PWID failing treatment are eligi-
ble for re-treatment without any loss in sustained viral response (SVR ᴨ). No immunity is
assumed because previous analyses showed it had little effect[6, 7].
Simulations and model parameters
Since most current HCV epidemics are not in the epidemic phase, we allowed the models to
reach a stable endemic state prior to initiating vaccination or treatment. Parameter values were
obtained from relevant literature (Table 1). The model was parameterised to a UK baseline sce-
nario where 40% of PWID have chronic HCV[17, 18], with the leaving rate μ including cessa-
tion of injecting (7.75% per year) and death (0.75% per year)[19, 20].
Baseline impact projections for the UK
To investigate the impact of vaccination in the UK, three vaccines were considered: a ‘low effi-
cacy’ vaccine that provides 50% protection against acquisition of infection for 5 years; a ‘mod-
erate efficacy’ vaccine that provides 70% protection for 10 years; and a ‘high efficacy’ vaccine
that provides 90% protection for 20 years. For each vaccine, we projected the reduction in
HCV chronic prevalence over time for different vaccination rates and the annual vaccination
rates needed to reduce prevalence and incidence by 25, 50 or 75% over 20 or 40 years.
Comparing the impact of vaccination with treatment
For the baseline UK scenario, the HCV treatment model was used to determine the annual
treatment rate required to reduce prevalence and incidence by 25, 50 and 75% after 20 or 40
HCV Vaccine, Direct-Acting Antivirals and PWID
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Fig 1. Model Schematics. Schematic for the mathematical models including vaccination (a) and treatment (b). The
parameters used are defined in Table 1.
doi:10.1371/journal.pone.0156213.g001
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years. These treatment rates were used to calculate the vaccination-to-treatment ratio, i.e. the
number of vaccinations needed per treatment to achieve the same impact; either on HCV
chronic prevalence or incidence. These treatment projections assumed parameters correspond-
ing to DAA treatments (Table 1).
Sensitivity analyses
For the baseline UK scenario, we performed univariate sensitivity analyses on the vaccination
rate needed for the moderate efficacy vaccine to halve chronic prevalence and incidence after
40 years. By undertaking parallel sensitivity analyses with the treatment model, we also deter-
mined the robustness of the vaccination-to-treatment ratios.
The sensitivity analyses explored how changes in initial HCV prevalence, injecting duration,
vaccine efficacy and duration of protection affected the required vaccination rates or vaccina-
tion-to-treatment ratios.
We also considered the effect of including heterogeneity in HCV transmission risk amongst
PWID. Half of PWID were assumed to be high-risk corresponding to the proportion of PWID
injecting crack or currently homeless in the UK[5], which were assumed to have 2 or 6 times
the HCV transmission risk of low-risk PWID[5, 6]. We explored the effect of no transitioning
between the risk groups or an average duration high-risk of 2 years[6] with low-risk PWID
transitioning to high-risk to balance this flow. We also consider a scenario where PWID are at
higher risk of HCV infection in their first year of injecting such that the prevalence amongst
Table 1. Model Parameters and Sources.
Parameter Symbol Value at Baseline Models Source
PWID leaving rate (cessation + death)
per year
μ 0.085a Both [19, 20]
Inflow rate of new injectors per year (per
1000 PWID)
θ 85b Both . . .
Infection rate per year λ 0.191c Both . . .
Initial chronic prevalence (%) . . . 40 Both [17, 18]
Proportion of new infections that
spontaneously clear
α 0.26 Both [18]
PWID vaccinated per 1000 per year Φv varied Vaccine . . .
PWID treated per 1000 per year Φt varied Treatment . . .
Duration of protection from vaccine
(years)
1/δ Vaccine . . .
‘Low efficacy’ vaccine 5
‘Moderate’ vaccine 10
‘High efficacy’ vaccine 20
Efficacy of vaccine (%) 100(1-η) Vaccine . . .
‘Low efficacy’ vaccine 50
‘Moderate’ vaccine 70
‘High efficacy’ vaccine 90
Proportion of infections cured with
treatment
ᴨ 90 Treatment [21]
Duration of treatment (weeks) 52/ω 12 Treatment [22]
a Based on a cessation rate of 7.75% per year, and a PWID death rate of 0.75%
b Set to be 1000μ in order to maintain a total population size of 1000 PWID
c Varied to fit chronic prevalence
doi:10.1371/journal.pone.0156213.t001
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recent PWID is half that of non-recent PWID[23]. All scenarios incorporating risk heterogene-
ity assumed random mixing because moderate like-with-like mixing has little effect[6, 24].
Lastly, we considered the implications of assuming immunity follows spontaneous clearance
of infection, modelled by assuming that PWID who spontaneously clear infection have the
same protection from reinfection as vaccinated PWID; i.e. 70% protection for 10 years.
Results
UK impact projections: vaccine
For the baseline UK scenario (40% chronic prevalence), annual vaccination rates of 100 per
1000 PWID could achieve a relative prevalence reduction among PWID of 35%, 65%, or 85%
after 40 years for the low (50% protection for 5 years), moderate (70% protection for 10 years),
and high efficacy (90% protection for 20 years) vaccines, respectively (Fig 2). These vaccination
rates result in a 61% vaccination coverage (proportion of current PWID who have ever been
vaccinated) after 20 years for the low efficacy vaccine, but higher coverage levels for the moder-
ate (68%) and high efficacy (75%) vaccines due to less re-vaccination. Vaccination rates below
50 per 1000 PWID per year will have modest impact (20% reduction in 50 years) with a low
efficacy vaccine, but could halve prevalence in 30 years with a high efficacy vaccine. For all sce-
narios, close to maximum impact is achieved after 50 years (S1 Fig).
Fig 3 shows that the low efficacy vaccine cannot halve prevalence over 20 years, but can over
40 years with high annual vaccination rates (162 per 1000 PWID) and resulting vaccination
coverage (72%). Higher efficacy vaccines require much lower vaccination rates or coverage lev-
els (44 per 1000 PWID annually or 38% respectively for the high efficacy vaccine) to achieve
the same impact over 40 years. Greater reductions can also be achieved; the moderate and high
efficacy vaccines can reduce prevalence by 75% over 40 years with annual vaccination rates of
138 and 79 per 1000 PWID, respectively. However, for the moderate vaccine (only scenario
where the vaccination rate is not maintained), this vaccination rate requires all susceptible
PWID to be vaccinated between years 7 and 21. For all vaccines considered, the vaccination
rate needed to halve prevalence is more than twice what is needed to reduce prevalence by 25%
over the same time period, and is nearly doubled again to reduce prevalence by 75%. Con-
versely, as the follow-up time is increased from 20 to 40 years, the annual number of vaccina-
tions needed to achieve the same impact decreases by up to 44%.
For all vaccines and impact levels considered, the required vaccination rates needed to
reduce HCV incidence over both 20 and 40 years (Fig 4) are smaller than that needed to reduce
prevalence to the same degree (Fig 3), suggesting that vaccination achieves reductions in inci-
dence faster than prevalence. For example, with the moderate vaccine, vaccination rates of 64
and 129 per 1000 PWID are needed to halve incidence and prevalence, respectively, over 20
years, and these reduce to 50 and 77 per 1000 PWID to halve incidence and prevalence over 40
years. Furthermore, for some of the scenarios considered, vaccination can achieve reductions
in incidence which cannot be achieved in prevalence. For example, the moderate efficacy vac-
cine could halve incidence over 20 years, with a vaccination rate of 120 per 1000 PWID, but
could not halve prevalence over the same timespan.
Sensitivity analysis. The sensitivity analysis (Fig 5) shows that the required vaccination
rate to halve chronic prevalence over 40 years is not sensitive to variations in chronic preva-
lence or the duration of injecting when varied from 10 to 5 or 20 years, although larger devia-
tions (S2 Fig) have greater effect. However, the duration of injecting has greater impact on the
vaccination rate needed to halve incidence over 40 years; with the vaccination rate increasing
by 46% if the duration of injecting was 5 years (Fig 6). As expected, the required vaccination
rates to halve prevalence and incidence are sensitive to the vaccine’s duration of protection.
HCV Vaccine, Direct-Acting Antivirals and PWID
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Indeed, for all vaccine efficacies considered, the impact on prevalence appears to be a logarith-
mic function of duration of protection (S3 Fig). Additionally, not allowing revaccination has
little effect except for vaccines with short durations of protection. Including immunity follow-
ing spontaneous clearance of infection has little impact, increasing the required vaccination
rates to halve prevalence or incidence by a relative 6 or 8%, respectively.
Fig 2. Impact Projections for HCV Vaccination. Projected relative reduction in chronic HCV prevalence
among PWID in the UK over time for various vaccination rates (Φv per 1000 PWID per year) with vaccines
that have (A) low: 50% protection for 5 years, (B) moderate: 70% protection for 10 years, or (C) high efficacy:
90% protection for 20 years.
doi:10.1371/journal.pone.0156213.g002
HCV Vaccine, Direct-Acting Antivirals and PWID
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Incorporating behavioural risk heterogeneity also has little effect if the model includes tran-
sitions between risk groups. However, if there is no transition between risk groups then the
required vaccination rates to halve chronic prevalence and incidence over 40 years increase
considerably (by up to 46%) if vaccinations are distributed randomly, and decrease substan-
tially (by up to 1/3) if high-risk PWID are targeted, while the desired prevalence and incidence
reductions are not achievable if only low-risk PWID are vaccinated. Conversely, if recent
PWID are higher-risk than non-recent PWID (9.4 times), then the required vaccination rates
are slightly higher (<24%) than at baseline if vaccination is distributed randomly.
Comparing the impact of vaccination to HCV treatment
Fig 7 shows that the vaccination rate required to achieve a 25% reduction in prevalence over 40
years is 3.4, 6 or 13 times greater than the treatment rate needed for the same impact, for the
high, moderate or low efficacy vaccines, respectively. These ratios increase for greater reduc-
tions in prevalence but decrease for increased follow-up times. For instance, the moderate effi-
cacy vaccine needs 8.4 and 7.6 vaccinations per treatment to halve prevalence over 20 and 40
years, respectively, and over 10 to reduce prevalence by 75% over 40 years.
Fig 3. Vaccination rates required to reduce HCV prevalence. Annual vaccination rate (per 1000 PWID) and coverage levels (after 20 years–shown
on top of bars) needed to reduce UK HCV chronic prevalence among PWID by a relative 25, 50 and 75% over 20 or 40 years, for a low (50% protection
for 5 years), moderate (70% protection for 10 years) or high efficacy vaccine (90% protection for 20 years). Asterisks mark scenarios in which vaccine
cannot achieve desired reduction in prevalence over time period.
doi:10.1371/journal.pone.0156213.g003
HCV Vaccine, Direct-Acting Antivirals and PWID
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When considering the impacts on incidence instead of prevalence, the vaccination-to-treat-
ment ratios are much lower, with only 5 vaccinations per treatment being needed to halve inci-
dence over 40 years for the moderate efficacy vaccine (Fig 8). Similar results are found for
other decreases in incidence, with much lower (by at least a third) vaccination-to-treatment
ratios being needed to reduce incidence rather than prevalence. However, in all scenarios con-
sidered, the vaccination-to-treatment ratios favor treatment, with the lowest ratio (1.9)
observed when considering the vaccination rate required to reduce incidence by 25% over 20
years with the high efficacy vaccine.
Sensitivity analysis. In the baseline scenario for the moderate efficacy vaccine, the annual
vaccination rates required to halve prevalence and incidence over 40 years were 7.6 and 4.9
times greater than the corresponding treatment rates, respectively. Figs 9 and 10 show that
these ratios are sensitive to the vaccine’s efficacy or duration of protection, whilst changes in
the treatment SVR have little effect (<11%). Baseline prevalence and injecting duration also
have a considerable effect, with the vaccination-to-treatment ratios decreasing dramatically
with HCV prevalence but increasing with injecting duration. Not allowing revaccination of
PWID or assuming immunity following spontaneous clearance of infection have negligible
impact (<1%) on the vaccination-to-treatment ratios.
Fig 4. Vaccination rates required to reduce HCV incidence. Annual vaccination rate (per 1000 PWID) and coverage levels (after 20 years–shown
on top of bars) needed to reduce UK HCV chronic incidence among PWID by a relative 25, 50 and 75% over 20 or 40 years, for a low (50% protection
for 5 years), moderate (70% protection for 10 years) or high efficacy vaccine (90% protection for 20 years). Asterisks mark scenarios in which
vaccination cannot achieve desired reduction in incidence over time period.
doi:10.1371/journal.pone.0156213.g004
HCV Vaccine, Direct-Acting Antivirals and PWID
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Incorporating behavioural risk heterogeneity across all PWID has negligible effect unless
vaccinations and treatments are risk targeted and PWID do not transition between risk groups.
If this is the case, then targeting high-risk PWID reduces the vaccination-to-treatment ratios,
whereas vaccinating low-risk PWID cannot halve prevalence or incidence over 40 years. Simi-
larly, assuming recent PWID are higher-risk increases the vaccination-to-treatment ratios for
halving prevalence and incidence irrespective of who is targeted.
Discussion
Although regulators and manufacturers will likely strive for a high efficacy vaccine, our analysis
suggests that even low efficacy HCV vaccines could have considerable impact; potentially halv-
ing HCV prevalence and incidence amongst PWID in 40 years for vaccine coverage levels com-
parable to what has been achieved for HBV amongst PWID in the UK, (72% in 2013[25]).
Higher efficacy vaccines could achieve these impacts with lower vaccine coverage levels (25–
56%) or over shorter time frames (20 years) and could achieve greater impact (75% reductions
in HCV incidence and prevalence over 20 and 40 years respectively). Although these impact
projections are favorable, our modeling suggests that similar reductions in HCV prevalence or
incidence could be achieved with 4–16 or 2–11 times fewer treatments, respectively. Nonethe-
less, at current HCV drug costs and even reduced costs, these ratios suggest that vaccination
Fig 5. Sensitivity Analysis: Vaccination rates required to reduce HCV prevalence.One-way sensitivity analyses on how specific changes in
model parameters affect the required annual vaccination rate per 1000 PWID (coverage level after 20 years shown above bars) for halving prevalence
among PWID over 40 years in the UK. The baseline scenario (dashed line) involves the moderate efficacy vaccine with 70% protection for 10 years,
and assumes no behavioural risk heterogeneity. Other baseline parameters are shown in the figure. Asterisks mark scenarios in which the vaccine
cannot halve prevalence over 40 years.
doi:10.1371/journal.pone.0156213.g005
HCV Vaccine, Direct-Acting Antivirals and PWID
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could be a much cheaper strategy for reducing HCV transmission than scaling-up treatment[7,
8, 24].
To optimize impact and efficiency with HCV treatment and vaccination strategies, it is
useful to understand when the benefits of vaccination are heightened. Importantly, our sen-
sitivity analysis suggests that its relative benefits compared to treatment improve markedly
in PWID populations with shorter injecting durations or higher HCV prevalences. Simi-
larly, HCV vaccination compares better to treatment for reducing HCV incidence than
reducing HCV prevalence, and when targeting higher-risk PWID[6]. This suggests that vac-
cination could be preferable to treatment in high prevalence settings or among high-risk
PWID subgroups, when treatment alone may not be suitable because of the considerable
risk of re-infection.
Limitations
Several limitations need to be considered. Chief among these is the speculative nature of the
vaccine characteristics. To counter this, we explored a range of efficacies and durations of pro-
tection to assess the effect of this uncertainty on our projections, and show that even low effi-
cacy vaccines could have considerable prevention utility.
Fig 6. Sensitivity Analysis: Vaccination rates required to reduce HCV incidence.One-way sensitivity analyses on how specific changes in model
parameters affect the required annual vaccination rate per 1000 PWID (coverage level after 20 years shown above bars) for halving incidence among
PWID over 40 years in the UK. The baseline scenario (dashed line) involves the moderate efficacy vaccine with 70% protection for 10 years, and
assumes no behavioural risk heterogeneity. Other baseline parameters are shown in the figure. Asterisks mark scenarios in which the vaccine cannot
halve incidence over 40 years.
doi:10.1371/journal.pone.0156213.g006
HCV Vaccine, Direct-Acting Antivirals and PWID
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Our model was primarily parameterised to the UK, and therefore our findings may not be
fully applicable to other settings. However, we performed extensive sensitivity analyses to show
how our results may vary for settings with different HCV prevalence or injecting duration.
We did not consider the possibility of a boosted immune response amongst vaccinated PWID
who are exposed to HCV (as occurs with other infections, e.g. pertussis[26]) to avoid further
speculation and over-complicating the model. If exposure to HCV boosted the immune response,
our projections would underestimate the impact of vaccination amongst PWID, especially for
vaccines with short duration of protection and in higher incidence settings with longer duration
of injecting. Our projections for the impact of vaccination should therefore be considered conser-
vative, further enforcing the conclusion that vaccination would be favorable to treatment.
Lastly, we only explored the impact of vaccination or treatment on their own, and neglected
the impact of other HCV prevention interventions such as OST and NSP. We do this to obtain
simple projections of the likely impact of a future vaccine, and to compare these projections
with what could be achieved with new HCV treatments. Indeed, if a HCV vaccine were avail-
able, it is highly likely that HCV prevention interventions and HCV treatment amongst PWID
would continue. Nevertheless, modelling studies project that continuing current treatment
rates with DAAs amongst PWID in the UK (4.1–27.4 per 1000 PWID) are unlikely to have
measurable impact in the next 15 years without further treatment scale-up[27, 28].
Fig 7. Vaccination-to-treatment ratios for reducing HCV prevalence. The number of vaccinations required per treatment for treatment and
vaccination to have the same impact on prevalence among PWID in the UK (25/50/75% reduction) over 20 or 40 years, for three different vaccine
scenarios: low (50% protection for 5 years); moderate (70% protection for 10 years); or high efficacy (90% protection for 20 years) Asterisks mark
scenarios in which the vaccine cannot achieve the desired reduction in HCV chronic prevalence over that time period.
doi:10.1371/journal.pone.0156213.g007
HCV Vaccine, Direct-Acting Antivirals and PWID
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Other studies
Our results are consistent with previous modeling which suggested that HCV vaccination
amongst PWID in San Francisco could substantially reduce the prevalence and incidence of
chronic HCV amongst PWID, especially if targeted to high-risk PWID[29]. Our analysis adds
additional insights on how the impact of vaccination may vary in different PWID settings, for
different vaccination durations, and makes a comparison of vaccination with new treatments.
Additionally, two cost-effectiveness studies have found that HCV vaccination of PWID in Bra-
zil[30] and Canada[31] would be cost-effective compared to ribavirin and interferon. Although
we did not undertake a cost-effectiveness analysis, our findings suggest that vaccination could
be cheaper than treatment for achieving large reductions in HCV prevalence.
Implications
Previous modeling has suggested that traditional prevention interventions (OST and NSP) are
unlikely to reduce HCV prevalence to low levels without HCV treatment scale-up[6, 24]. Our
analysis suggests that vaccination could also be an important intervention strategy.
Fig 8. Vaccination-to-treatment ratios for reducing HCV incidence. The number of vaccinations required per treatment for treatment and
vaccination to have the same impact on incidence among PWID in the UK (25/50/75% reduction) over 20 or 40 years, for three different vaccine
scenarios: low (50% protection for 5 years); moderate (70% protection for 10 years); or high efficacy (90% protection for 20 years) Asterisks mark
scenarios in which the vaccine cannot achieve the desired reduction in HCV chronic incidence over that time period.
doi:10.1371/journal.pone.0156213.g008
HCV Vaccine, Direct-Acting Antivirals and PWID
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The infrastructure for HCV vaccination is already in place in many settings through existing
HBV vaccination programmes for PWID, including through NSPs[32], prisons[33] or drug
treatment centres[34] as suggested by the World Health Organization[35]. Vaccinating in such
settings can achieve high coverage amongst PWID. For instance, in the UK only people at
high-risk of infection are vaccinated against HBV and high coverage amongst PWID (72% in
2013[25]) has been achieved due to vaccination programs in prison (where high incarceration
rates amongst PWID[36, 37] provide an ideal opportunity to vaccinate PWID) and at drug ser-
vices[38]. Additionally, small cash incentives can increase both the coverage and completion
rate of HBV vaccination amongst PWID[39, 40]. This suggests that when available, HCV vac-
cination may be more easily scaled-up, especially in the UK, than HCV treatment which would
require greater medical infrastructure and expertise due to the testing needed to assess treat-
ment eligibility, progress and success[41]. Also, fewer follow-ups for a vaccination strategy
may be necessary as some vaccines are partially effective even with a single dose. However, if
multiple doses are required, this could reduce effectiveness; for example, the recombinant hep-
atitis B vaccine Engerix-B achieves seroprotection rates of only 5.4–20.4% after the first dose,
with increased protection obtained after subsequent doses[42]. Hence, poor adherence to a vac-
cination schedule could limit the impact of a HCV vaccine. However, in 2014, 83% of PWID in
Scotland who had received at least one dose of HBV vaccination had received all 3 doses[43],
Fig 9. Sensitivity Analysis: Vaccination-to-treatment ratios for reducing HCV prevalence.One-way sensitivity analyses on how specific changes
in model parameters affect the ratio of the required annual vaccination to treatment rate needed to halve prevalence among PWID over 40 years in the
UK for a vaccine with 70% efficacy and duration of protection of 10 years. The baseline scenario (dashed line) assumed no behavioural risk
heterogeneity with other baseline parameters shown in the figure. Asterisks mark scenarios in which the vaccine cannot halve prevalence over 40
years.
doi:10.1371/journal.pone.0156213.g009
HCV Vaccine, Direct-Acting Antivirals and PWID
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suggesting that a multi-dose schedule may not limit the impact of HCV vaccination in the UK.
Furthermore, a booster dose may be required considerably later than the initial dose (e.g. 5
years). Although there is limited data to inform how PWID would adhere to such a schedule, it
is likely that delays in receiving the booster dose could limit the impact of such a vaccine com-
pared to a vaccine providing similar protection without needing a booster dose, as is modelled
in our study.
Importantly, the costs of HCV vaccination are likely to be far lower than the current cost of
HCV treatment in high-income countries. For instance, the cost of vaccinating PWID for HBV
in a NSP or prison setting has been estimated to be less than $200 per PWID in the USA[44,
45]. Even if the HCV vaccine cost was towards the high end of currently available vaccines
($500 for the meningitis B vaccine, Bexsero) the cost per PWID would likely still be at least 50
times less than the current cost of HCV treatment in high income settings. Although the costs
of HCV treatment are likely to decrease in coming years, the costs of HCV vaccination, when
available, are still likely to be a fraction of the cost of treatment. Furthermore, although some
lower and middle income countries are already purchasing the new HCV treatments at under
$900 per 12 week course[9] as well as generic Sofosbuvir from as little as $483 per 12 week
course[46], similar price differentials between developed and developing countries are also
likely to apply to a vaccine. In addition, infrastructure issues for scaling-up HCV case-finding
Fig 10. Sensitivity Analysis: Vaccination-to-treatment ratios for reducing HCV incidence.One-way sensitivity analyses on how specific changes
in model parameters affect the ratio of the required annual vaccination to treatment rate needed to halve incidence among PWID over 40 years in the
UK for a vaccine with 70% efficacy and duration of protection of 10 years. The baseline scenario (dashed line) assumed no behavioural risk
heterogeneity with other baseline parameters shown in the figure. Asterisks mark scenarios in which the vaccine cannot halve incidence over 40 years.
doi:10.1371/journal.pone.0156213.g010
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and treatment may be more challenging in these settings because of the poor level of healthcare
available, further favoring the introduction of a HCV vaccine.
Lastly, there is little evidence of a protective immune response following treatment with
DAAs, which may limit the use of treatment as a solitary prevention intervention, especially in
high prevalence settings where reinfection is likely. However, since treatment and vaccination
would be targeted to different PWID, it is possible that treatment and vaccination could act in
unison, with HCV uninfected PWID receiving vaccination and HCV infected PWID receiving
treatment, and possibly then vaccination.
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